Intra-Cellular Therapies (ITCI) Misses Q3 EPS by 7c ; Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. KLAC
10. ETSY

Go back to Intra-Cellular Therapies (ITCI) Misses Q3 EPS by 7c ; Offers Guidance

Intra-Cellular Therapies (ITCI) PT Raised to $79 at Goldman Sachs

October 30, 2024 4:38 PM EDT

Goldman Sachs analyst Corinne Jenkins raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $79.00 (from $74.00) while maintaining a Neutral rating.

The analyst comments "Focus remains on commercial execution ahead of MDD launch. ITCI reported 3Q24 revenues of $175.4M, slightly higher than FactSet consensus ($172.3M, +2%) and in-line with GS estimate ($175.2M, 0%). The company also modestly raised and narrowed the range... More